Koumine
(Synonyms: 钩吻素子) 目录号 : GN10748
Koumine是从传统中药钩吻(Gelsemium elegans)中提取的一种主要活性生物碱,具有多种药理作用,包括抗炎和免疫调节等。
Cas No.:1358-76-5
Sample solution is provided at 25 µL, 10mM.
Koumine is a major active alkaloid extracted from the traditional Chinese medicinal herb Gelsemium elegans, and it exhibits a variety of pharmacological effects, including anti-inflammatory and immunomodulatory activities[1-2]. Koumine can modulate the activity of multiple signaling pathways, such as NF-κB, MAPK, and PI3K/Akt[3]. Studies have shown that Koumine can alleviate neuropathic pain, suppress neuroinflammation, and protect against neuronal damage[4].
In vitro, treatment of human hepatocellular carcinoma cells (Huh-7 and SNU-449) with Koumine (100–800μg/mL) significantly inhibited cell proliferation and promoted apoptosis. Koumine reduced mitochondrial membrane potential, increased intracellular reactive oxygen species (ROS) levels, and suppressed the phosphorylation of ERK, p38, p65, and IκBα. Additionally, Koumine upregulated the expression of pro-apoptotic proteins cleaved-Caspase-3 and Bax, while downregulating the anti-apoptotic protein Bcl-2[5]. In RAW264.7 macrophages, pretreatment with Koumine (100–400μg/mL) significantly inhibited lipopolysaccharide (LPS)-induced inflammatory responses. Koumine reduced the expression of inducible nitric oxide synthase (iNOS) and the production of nitric oxide (NO), and decreased the secretion levels of pro-inflammatory cytokines interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α). Koumine also inhibited the phosphorylation of p65 and IκBα in the NF-κB signaling pathway and reduced NF-κB DNA-binding activity. Furthermore, Koumine significantly suppressed the phosphorylation of extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase (p38 MAPK)[6].
In vivo, oral administration of Koumine (0.6–15mg/kg/day) to rats with adjuvant-induced arthritis (AIA) and collagen-induced arthritis (CIA) significantly reduced arthritis index scores, mechanical hyperalgesia, and paw swelling. Koumine also inhibited abnormal increases in thymus and liver weights and improved joint space narrowing and bone destruction. Moreover, Koumine significantly decreased the protein and mRNA expression levels of pro-inflammatory cytokines IL-1β and TNF-α in serum and joint tissues, and suppressed the elevation of anti-type II collagen antibodies (anti-CII IgG) in serum [7]. In a Sprague-Dawley (SD) rat model of non-alcoholic fatty liver disease (NAFLD) induced by a high-fat diet, Koumine (0.056, 0.28, and 1.4mg/kg) was administered intraperitoneally once daily for two weeks starting from the 16th week of model establishment. Koumine dose-dependently and significantly reduced serum levels of triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), alanine aminotransferase (ALT), and aspartate aminotransferase (AST), while increasing high-density lipoprotein cholesterol (HDL-C) levels. Koumine also decreased the liver index, improved hepatic steatosis, and significantly reduced the production and mRNA expression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-17A, IFN-γ) in the liver, while increasing the expression of the anti-inflammatory cytokine IL-10. Additionally, Koumine modulated the proportions of CD4⁺ T cell subsets in the liver, inhibited the differentiation of Th1 and Th17 cells, and promoted the generation of Th2 and Treg cells, thereby exerting immunomodulatory effects and significantly alleviating the pathological progression of NAFLD[8].
References:
[1] Shoaib RM, Zhang JY, Mao XF, et al. Gelsemine and koumine, principal active ingredients of Gelsemium, exhibit mechanical antiallodynia via spinal glycine receptor activation-induced allopregnanolone biosynthesis. Biochem Pharmacol. 2019 Mar;161:136-148.
[2] Xiong B, Jin G, Xu Y, et al. Identification of Koumine as a Translocator Protein 18 kDa Positive Allosteric Modulator for the Treatment of Inflammatory and Neuropathic Pain. Front Pharmacol. 2021 Jun 24;12:692917.
[3] Lin SK, Chen ST, Zhan Y, et al. The alleviatory effects of koumine on MSU-induced gouty arthritis via the TLR4/NF-κB/NLRP3 pathway. Basic Clin Pharmacol Toxicol. 2024 Aug;135(2):133-147.
[4] Xiong B, Zhong Z, Chen C, et al. The anxiolytic effect of koumine on a predatory sound stress-induced anxiety model and its associated molecular mechanisms. Phytomedicine. 2022 Aug;103:154225.
[5] Yuan Z, Liang Z, Yi J, et al. Koumine Promotes ROS Production to Suppress Hepatocellular Carcinoma Cell Proliferation Via NF-κB and ERK/p38 MAPK Signaling. Biomolecules. 2019 Oct 2;9(10):559.
[6] Guo J, Ding W, Cai S, et al. Polydatin radiosensitizes lung cancer while preventing radiation injuries by modulating tumor-infiltrating B cells. J Cancer Res Clin Oncol. 2023 Sep;149(12):9529-9542.
[7] Yang J, Cai HD, Zeng YL, et al. Effects of Koumine on Adjuvant- and Collagen-Induced Arthritis in Rats. J Nat Prod. 2016 Oct 28;79(10):2635-2643.
[8] Yue R, Jin G, Wei S, et al. Immunoregulatory Effect of Koumine on Nonalcoholic Fatty Liver Disease Rats. J Immunol Res. 2019 Feb 17;2019:8325102.
Koumine是从传统中药钩吻(Gelsemium elegans)中提取的一种主要活性生物碱,具有多种药理作用,包括抗炎和免疫调节等[1-2]。Koumine可调节NF-κB、MAPK和PI3K/Akt等多个信号通路活性[3]。研究表明,Koumine可缓解神经病理性疼痛、抑制神经炎症,抵抗焦虑,并对神经元损伤具有保护作用[4]。
在体外,Koumine(100–800μg/mL)处理人肝癌细胞(Huh-7和SNU-449),显著抑制了细胞增殖并促进了细胞凋亡,降低了线粒体膜电位,增加了细胞内活性氧(ROS)水平,抑制了ERK、p38、p65和IκBα的磷酸化,上调了促凋亡蛋白cleaved-Caspase-3和Bax的表达,下调了抗凋亡蛋白Bcl-2的表达[5]。Koumine(100–400μg/mL)预处理RAW264.7巨噬细胞后,显著抑制了脂多糖(LPS)诱导的炎症反应,降低了诱导型一氧化氮合酶(iNOS)蛋白表达及一氧化氮(NO)的生成,减少了促炎细胞因子白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)的分泌水平。同时,Koumine抑制了核因子κB(NF-κB)信号通路中p65和IκBα的磷酸化,降低了NF-κB的DNA结合活性。此外,Koumine还显著抑制了细胞外信号调节激酶(ERK)和p38丝裂原活化蛋白激酶(p38 MAPK)的磷酸化[6]。
在体内,Koumine(0.6–15mg/kg/day)通过灌胃方式处理患有佐剂诱导性关节炎(AIA)和胶原诱导性关节炎(CIA)的大鼠,显著减轻了关节炎指数评分、机械性痛觉过敏和足爪肿胀程度,抑制了胸腺和肝脏重量的异常增加,改善了关节间隙狭窄和骨破坏。此外,Koumine还显著降低了血清和关节组织中促炎细胞因子IL-1β和TNF-α的蛋白及mRNA表达水平,并抑制了血清中抗II型胶原抗体(anti-CII IgG)的升高[7]。Koumine(0.056、0.28和1.4mg/kg)通过腹腔注射给药,用于治疗高脂饮食诱导的非酒精性脂肪性肝病(NAFLD)Sprague-Dawley(SD)大鼠模型,给药时间为模型建立后第16周开始,每日一次,持续两周。Koumine以剂量依赖性方式显著降低NAFLD大鼠血清中的甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、丙氨酸氨基转移酶(ALT)和天门冬氨酸氨基转移酶(AST)水平,升高高密度脂蛋白胆固醇(HDL-C)水平,减少肝脏指数,改善肝细胞脂肪样病变,并显著降低肝脏中促炎细胞因子(TNF-α、IL-1β、IL-6、IL-17A、IFN-γ)的产生和mRNA表达,同时增加抗炎细胞因子IL-10的表达。此外,Koumine还可调节肝脏中CD4+ T细胞亚群的比例,抑制Th1和Th17细胞的分化,促进Th2和Treg细胞的生成,从而发挥免疫调节作用,显著缓解NAFLD的病理进程[8]。
Cell experiment [1]: | |
Cell lines | Human hepatocellular carcinoma (HCC) cells (Huh-7 and SNU-449) |
Preparation Method | Huh-7 and SNU-449 cells were cultured in DMEM or RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) at 37°C in 5% CO₂. Upon reaching the logarithmic growth phase, cells were treated with Koumine at various concentrations (100, 200, 400, and 800μg/mL) for 24 hours. |
Reaction Conditions | 100, 200, 400, and 800μg/mL; 24 hours. |
Applications | Koumine significantly inhibited HCC cell proliferation in a dose-dependent manner. Koumine also promoted apoptosis, and upregulation of pro-apoptotic proteins (cleaved caspase-3 and Bax) with concurrent downregulation of anti-apoptotic protein Bcl-2. Additionally, Koumine treatment led to mitochondrial dysfunction (decreased mitochondrial membrane potential) and elevated intracellular ROS levels. These effects were accompanied by inhibition of ERK/p38 MAPK and NF-κB signaling pathways (reduced phosphorylation of ERK, p38, p65, and IκBα). |
Animal experiment [2]: | |
Animal models | Sprague-Dawley rats |
Preparation Method | Nonalcoholic fatty liver disease (NAFLD) was induced by feeding rats a high-fat diet (containing 1% cholesterol, 0.1% bile salt, 10% lard, 5% egg yolk powder and whole milk powder) for 16 weeks. After 16 weeks, rats were intraperitoneally injected with Koumine (0.056, 0.28, or 1.4mg/kg) or saline once daily for 2 weeks. At the end of the 18th week. |
Dosage form | 0.056, 0.28, and 1.4mg/kg; i.p. |
Applications | Koumine significantly reduced serum levels of triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), alanine aminotransferase (ALT), and aspartate aminotransferase (AST), while increasing high-density lipoprotein cholesterol (HDL-C) levels. Koumine decreased liver index and improved hepatic steatosis and inflammatory infiltration. Koumine also reduced the production and mRNA expression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-17A, IFN-γ) and increased the anti-inflammatory cytokine IL-10. Furthermore, Koumine modulated T cell subsets by decreasing Th1 and Th17 cells and increasing Th2 and Treg cells in the liver, thereby exerting immunomodulatory and anti-inflammatory effects against NAFLD. |
References: |
Cas No. | 1358-76-5 | SDF | |
别名 | 钩吻素子 | ||
Canonical SMILES | CN1CC2(C3CC4C5=NC6=CC=CC=C6C52CC1C3CO4)C=C | ||
分子式 | C20H22N2O | 分子量 | 306.4 |
溶解度 | ≥ 29mg/mL in DMSO with ultrasonic | 储存条件 | 4°C, away from moisture and light |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 3.2637 mL | 16.3185 mL | 32.6371 mL |
5 mM | 0.6527 mL | 3.2637 mL | 6.5274 mL |
10 mM | 0.3264 mL | 1.6319 mL | 3.2637 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet